Ephedra and the FDA

DSpace/Manakin Repository

Ephedra and the FDA

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Ehlers, Brandi E. en_US
dc.date.accessioned 2012-06-07T20:27:11Z
dc.date.issued 2001 en_US
dc.identifier.citation Ephedra and the FDA (2001 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852148
dc.description.abstract The adverse events experienced after ingesting ephedra and other dietary supplements have demonstrated the need for FDA intervention. The FDA has an important role to play in safeguarding the health and safety of the American public. The FDA has been criticized as contravening the Congressional intent underlying DSHEA because of its attempts to regulate the dietary supplement industry, when in fact, the FDA has not overstepped its bounds. The agency has only taken the measures it felt necessary to protect the public and "implement a complex and ambiguous law." However, the FDA does need to focus on more effective procedures and systems for collecting adverse event reports and could take additional steps toward public awareness. In order for the FDA to address the overall problems with the regulating the dietary supplement industry efficiently and effectively, they will need additional funding. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject ephedra en
dc.subject FDA en
dc.subject regulation en
dc.subject dietary supplement en
dc.title Ephedra and the FDA en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-06-07T20:27:11Z

Files in this item

Files Size Format View
Ehlers.pdf 328.4Kb PDF View/Open
Ehlers.rtf 186.5Kb RTF file View/Open
Ehlers.html 176.0Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters